Nanexa receives notification of imminent US patent grant

 

 

Pressrelease

 

Uppsala 12thDecember 2018

 

Nanexa receives notification of imminent US patent grant

 

The US patent office has now issued an “Issue Notification” in respect Nanexa´s US patent application regarding the Company’s drug delivery platform PharmaShell®.  Although, technically-speaking, a patent can be withdrawn from issuance at any time up to the actual grant, should new information come to light, all being well, the Issue Notification states that a patent will issue on January 1, 2019 as US 10,166,198.

 

Nanexa’s CEO David Westberg comments:

The next step of the US Patent Office’s granting process has now taken place.  We look forward to obtaining an issued US patent for PharmaShell® in accordance with the estimated timeline.

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.